share_log

Novo Integrated Sciences | 8-K: Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股sec公告 ·  04/15 16:35
Moomoo AI 已提取核心訊息
On April 15, 2024, Novo Integrated Sciences, Inc. (Novo), a healthcare company listed on the Nasdaq Capital Market under the symbol NVOS, released its financial results for the second fiscal quarter ending February 29, 2024. The company, headquartered in Bellevue, Washington, reported a 24% increase in revenues to $3,170,592 compared to the same period in the previous year, primarily due to an increase in product sales. Despite the revenue growth, Novo experienced a net loss of $2,746,128 for the quarter, which is a 41% improvement from the $4,621,355 loss reported for the quarter ending February 28, 2023. The reduction in net loss is attributed to an increase in gross profit and a decrease in other expenses. Novo also highlighted the conversion of a promissory note into common stock, which settled the...Show More
On April 15, 2024, Novo Integrated Sciences, Inc. (Novo), a healthcare company listed on the Nasdaq Capital Market under the symbol NVOS, released its financial results for the second fiscal quarter ending February 29, 2024. The company, headquartered in Bellevue, Washington, reported a 24% increase in revenues to $3,170,592 compared to the same period in the previous year, primarily due to an increase in product sales. Despite the revenue growth, Novo experienced a net loss of $2,746,128 for the quarter, which is a 41% improvement from the $4,621,355 loss reported for the quarter ending February 28, 2023. The reduction in net loss is attributed to an increase in gross profit and a decrease in other expenses. Novo also highlighted the conversion of a promissory note into common stock, which settled the total principal and interest owed. The company emphasized its focus on operational efficiencies, margin improvement, and the pursuit of nontraditional financing opportunities to support its three-pillar business model, which includes service networks, technology, and product development. Novo's CEO, Robert Mattacchione, reaffirmed the company's commitment to commercializing proprietary products and expanding essential services for non-catastrophic healthcare delivery.
2024年4月15日,在納斯達克資本市場上市的醫療保健公司諾和綜合科學有限公司(Novo)發佈了截至2024年2月29日的第二財季財務業績。該公司總部位於華盛頓州貝爾維尤,報告收入與去年同期相比增長了24%,達到3,170,592美元,這主要是由於產品銷售的增加。儘管收入增長,但Novo本季度淨虧損2746,128美元,較截至2023年2月28日的季度公佈的4,621,355美元虧損增長了41%。淨虧損的減少歸因於毛利潤的增加和其他支出的減少。Novo還強調了將期票轉換爲普通股的情況,這結清了所欠的本金和利息總額。該公司強調將重點放在運營效率、利潤率提高和追求非傳統融資機會上,以支持其三大支柱業務模式,包括服務網絡、技術和產品開發。Novo首席執行官羅伯特·馬塔基奧內重申了公司對專有產品商業化和擴大非災難性醫療保健服務的基本服務的承諾。
2024年4月15日,在納斯達克資本市場上市的醫療保健公司諾和綜合科學有限公司(Novo)發佈了截至2024年2月29日的第二財季財務業績。該公司總部位於華盛頓州貝爾維尤,報告收入與去年同期相比增長了24%,達到3,170,592美元,這主要是由於產品銷售的增加。儘管收入增長,但Novo本季度淨虧損2746,128美元,較截至2023年2月28日的季度公佈的4,621,355美元虧損增長了41%。淨虧損的減少歸因於毛利潤的增加和其他支出的減少。Novo還強調了將期票轉換爲普通股的情況,這結清了所欠的本金和利息總額。該公司強調將重點放在運營效率、利潤率提高和追求非傳統融資機會上,以支持其三大支柱業務模式,包括服務網絡、技術和產品開發。Novo首席執行官羅伯特·馬塔基奧內重申了公司對專有產品商業化和擴大非災難性醫療保健服務的基本服務的承諾。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息